Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu

HANGZHOU,Chinaand SHAOXING,China,Jan.2,2019 --Ascletis Pharma Inc. (1672.HK),a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral,cancer and fatty liver diseases,announces today thatGanovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Chengdu,Sichuan Province. This is another important milestone for patient access to Ganovo® after its recent enrollment in Tianjin Basic Medical Insurance Program under capped-reimbursement per patient pilot program and Shaoxing government funding subsidy program.

Ganovo® is the first direct-acting antiviral agent (DAA) developed and commercialized by a domestic company in China. Ganovo®inhibits the hepatitis C virus (HCV) NS3/4A protease that is critical to HCV replication. In the phase III clinical trial conducted in Mainland China,Ganovo regimen (Ganovo®in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in HCV genotype 1 non-cirrhotic patients with a 12-week treatment duration. Ganovo®,in combination with Ravidasvir,an NDA accepted HCV NS5A inhibitor,and ribavirin,forms an all-oral,interferon-free HCV therapy (RDV/DNV Regimen),which offers a cure rate of 99% (SVR12) in the phase II/III clinical trial of HCV genotype 1 non-cirrhotic patients with 12-week treatment duration. In the same phase II/III clinical trial,RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12) for patients with baseline NS5A resistance mutations.

Jinzi J. Wu,Ph.D.,Ascletis' Founder,Chairman and CEO commented,"I'm very glad that Ganovo® has gained yet another endorsement from the medical insurance authorities and is well-recognized in the clinical community for its efficacy and safety. We anticipate Ganovo®will gain additional reimbursement access and further benefit hepatitis C patients in China."